CLINICAL_TRIALS
trial_result
· 2014-08-21
Clinical Trial Update: Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in Premenopausal Women With Symptomatic Uterine Fibroids [Phase 3]
Summary
A Phase 3 study evaluating Proellex (CDB-4124) in premenopausal women with symptomatic uterine fibroids has been terminated, with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Repros Therapeutics Inc. | Conditions: Uterine Fibroids | Phase 3 | Status: TERMINATED | Results posted: 2014-08-21